Diabetes drug appears effective for weight loss, study shows That compared with a loss of 4.6 percent for a 1.8 mg dose and just 2 percent loss for those who got a placebo. But with obesity becoming a global health crisis, Novo Nordisk now sees the medicine as a potentially lucrative weight loss drug at a higher than currently approved dose. and European regulators for 3 mg liraglutide for weight loss. Food and Drug Administration weight loss drug criteria, leaving safety as the main hurdle to approval. It is approved to treat type 2 diabetes in the United States at 1.2 mg and 1.8 mg. In the 56-week study of 846 overweight or obese adults with type 2 diabetes, a daily injection of 3 milligrams of Victoza led to significantly greater weight loss than did a placebo. Kushner said there were no cases of either during the trial. A lively debate is likely when a panel of experts meets in September to discuss the drug before the FDA makes a decision. http://www.foxnews.com/health/2014/06/16/diabetes-drug-appears-effective-for-weight-loss-study-sh ows/ Nausea typically diminishes after four to eight weeks, Kushner said. There was a 9.2 percent drop out rate in the 3 mg group, with more than half due to gastrointestinal disorders, such as nausea and diarrhea, which are common to drugs in this class. Weight loss had been viewed as a beneficial side effect of Victoza as obesity is a leading cause of type 2 diabetes. Some two thirds of Americans are classified as overweight or obese. In the study, called Scale, 50 percent of patients taking 3 mg Victoza lost at least 5 percent of body weight and 22 percent dropped more than 10 percent.. Danish drugmaker Novo Nordisk is awaiting approval decisions from U.S. Robert Kushner, an obesity specialist and one of the trial's investigators, said in a telephone interview. Patients taking the 3 mg dose of the drug, known chemically as liraglutide, had a mean loss of 5.9 percent of body weight. All patients were also put on a diet and exercise program. The FDA has defended Victoza's safety against calls for its removal from the market by consumer watchdog Public Citizen, which says it raises the risk of thyroid cancer and pancreatitis. The results were presented at the American Diabetes Association meeting in San Francisco. Novo Nordisk's big-selling diabetes drug Victoza appears to be an effective weight loss therapy, data from a late-stage clinical trial presented on Saturday demonstrated. "We currently cannot predict who's going to respond to which medication and that's why it's so helpful to have multiple medications," he said. Victoza had global sales of about $542 million in the first quarter. "Even individuals without diabetes may be very responsive to this hormonal approach", compared with drugs that work on the brain to suppress appetite, he added.

Diabetes drug appears effective for weight loss, study shows

Download PDF Report

Upload
efficaciousphys43
View
49
Download
0

Embed Size (px)

Citation preview

Diabetes drug appears effective for weight loss, study shows

That compared with a loss of 4.6 percent for a 1.8 mg dose and just 2 percent loss for those who gota placebo. But with obesity becoming a global health crisis, Novo Nordisk now sees the medicine asa potentially lucrative weight loss drug at a higher than currently approved dose. and Europeanregulators for 3 mg liraglutide for weight loss. Food and Drug Administration weight loss drugcriteria, leaving safety as the main hurdle to approval. It is approved to treat type 2 diabetes in theUnited States at 1.2 mg and 1.8 mg.

In the 56-week study of 846 overweight or obese adults with type 2 diabetes, a daily injection of 3milligrams of Victoza led to significantly greater weight loss than did a placebo.

Kushner said there were no cases of either during the trial. A lively debate is likely when a panel ofexperts meets in September to discuss the drug before the FDA makes a decision.

http://www.foxnews.com/health/2014/06/16/diabetes-drug-appears-effective-for-weight-loss-study-shows/

Nausea typically diminishes after four to eight weeks, Kushner said.

There was a 9.2 percent drop out rate in the 3 mg group, with more than half due to gastrointestinaldisorders, such as nausea and diarrhea, which are common to drugs in this class.

Weight loss had been viewed as a beneficial side effect of Victoza as obesity is a leading cause oftype 2 diabetes. Some two thirds of Americans are classified as overweight or obese.

In the study, called Scale, 50 percent of patients taking 3 mg Victoza lost at least 5 percent of bodyweight and 22 percent dropped more than 10 percent.. Danish drugmaker Novo Nordisk is awaitingapproval decisions from U.S. Robert Kushner, an obesity specialist and one of the trial'sinvestigators, said in a telephone interview.

Patients taking the 3 mg dose of the drug, known chemically as liraglutide, had a mean loss of 5.9percent of body weight. All patients were also put on a diet and exercise program.

The FDA has defended Victoza's safety against calls for its removal from the market by consumerwatchdog Public Citizen, which says it raises the risk of thyroid cancer and pancreatitis.

The results were presented at the American Diabetes Association meeting in San Francisco.

Novo Nordisk's big-selling diabetes drug Victoza appears to be an effective weight loss therapy, datafrom a late-stage clinical trial presented on Saturday demonstrated.

"We currently cannot predict who's going to respond to which medication and that's why it's sohelpful to have multiple medications," he said.

Victoza had global sales of about $542 million in the first quarter. "Even individuals without diabetesmay be very responsive to this hormonal approach", compared with drugs that work on the brain tosuppress appetite, he added.

http://www.foxnews.com/health/2014/06/16/diabetes-drug-appears-effective-for-weight-loss-study-shows/